| 难治性重症肌无力的治疗管理 |
| |
| 引用本文： | 董梦琪,郭军红,张金.难治性重症肌无力的治疗管理[J].国际免疫学杂志,2017,40(2). |
| |
| 作者姓名： | 董梦琪 郭军红 张金 |
| |
| 作者单位： | 山西医科大学第一医院, 太原,030001 |
| |
| 基金项目： | 山西省卫生计生委科研项目(2015030)Scientific Research Project of Health and Family Planning Commission of Shanxi Province |
| |
| 摘 要： | 重症肌无力是一种影响突触后膜的自身免疫性疾病,病态疲劳性肌无力为主要特点.近年来较多研究显示多种免疫抑制剂和单克隆抗体对重症肌无力的治疗具有重要作用.进一步熟知难治性重症肌无力的治疗进展对于改善患者的临床症状具有深远意义.
|
| 关 键 词： | 难治性重症肌无力 单克隆抗体 免疫抑制剂 手术 |
The therapeutic management of refractory myasthenia gravis |
| |
| Dong Mengqi,Guo Junhong,Zhang Jin.The therapeutic management of refractory myasthenia gravis[J].International Journal of Immunology,2017,40(2). |
| |
| Authors: | Dong Mengqi Guo Junhong Zhang Jin |
| |
| Abstract: | Myasthenia gravis is an acquired autoimmune disease,which influences the postsynaptic membrane and makes affected muscle pathological fatigue.In recent years,many research results show that a variety of immune inhibitors and monoclonal antibody play an important role in the treatment of myasthenia gravis.Having a good knowledge of the treatment of refractory myasthenia gravis lay a foundation for improving the clinical manifestations. |
| |
| Keywords: | Refractory myasthenia gravis Monoclonal antibody Immune inhibitors Surgery |
| 本文献已被 万方数据 等数据库收录！ |
|
